Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1052837/000104746905006618/a2153526z10-k.htm
Exhibit 99.1
FOR IMMEDIATE RELEASE |
NEWS |
Contact: |
Ami Knoefler |
|
Senior Director |
|
Corporate Communications and Investor Relations |
|
510-284-6350 or 510-284-6605 |
ABGENIX ANNOUNCES 2004 FOURTH QUARTER AND FULL YEAR
FINANCIAL RESULTS
FREMONT, Calif., February 22, 2005 - Abgenix, Inc. (Nasdaq:ABGX) today reported financial results for the fourth quarter and full year ended December 31, 2004.
For the quarter ended December 31, 2004, the company reported a net loss of $42.9 million or $0.48 per share, compared to a net loss of $53.0 million or $0.60 per share for the same period in 2003. The net loss for the fourth quarter of 2003 included a $7.9 million impairment charge related to an investment. The company ended 2004 with $416.3 million in cash, cash equivalents and marketable securities.
Revenues for the fourth quarter of 2004 were $5.9 million, compared to $6.4 million for the same period in 2003. Contract revenues for the quarter ended December 31, 2004 primarily consisted of milestones and fees from technology licensing agreements, including milestones from Human Genome Sciences, Chiron and CuraGen for advancing XenoMouse®-derived antibodies into the clinical phase. The companys revenues typically result from milestone payments and fees associated with various collaborations and technology licensing agreements.
Operating expenses for the fourth quarter of 2004 were $47.2 million, compared to $51.8 million for the same period in 2003. The majority of fourth quarter 2004 research and development costs related to advancement of the companys proprietary clinical product candidates, including its lead oncology product candidate, panitumumab, and ABX-PTH, an antibody for secondary hyperparathyroidism (SHPT). Included in both periods were manufacturing start-up costs related to operating the companys antibody production facility. A portion of the costs associated with this facility will continue to be classified as manufacturing start-up costs until the facility is operating at normal capacity.
-more-
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Abgenix Inc.
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1052837/000104746905006618/a2153526z10-k.htm
Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.
ContinueRead positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.
ContinueRemove data columns and navigations in order to see much more filing content and tables in one view
ContinueRead both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q
ContinueExport Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis
ContinueGet one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports
Continue for FREEOur Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not
ContinueOur Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity
ContinueSee how over 70
Growth, Profitability and Financial Ratios perform over 10 Years